- Conditions
- Malignant Glioma, Glioblastoma Multiforme, GBM, Astrocytoma, Oligodendroglioma
- Interventions
- TM-601
- Drug
- Lead sponsor
- TransMolecular
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 7
- States / cities
- Birmingham, Alabama • Los Angeles, California • Chicago, Illinois + 4 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 289–312
of 868
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Cystic Fibrosis
- Interventions
- standardized turmeric root extract
- Drug
- Lead sponsor
- Ramsey, Bonnie, MD
- Individual
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • Seattle, Washington
- Conditions
- Advanced Solid Tumor
- Interventions
- ET0038
- Drug
- Lead sponsor
- Etern BioPharma (Shanghai) Co., Ltd
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Advanced Malignant Solid Neoplasm, Extensive Stage Lung Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
- Interventions
- Atezolizumab, Niraparib, Quality-of-Life Assessment, Questionnaire Administration, Temozolomide
- Biological · Drug · Other
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Type 2 Diabetes
- Interventions
- SK-0403, Placebo, Sitagliptin
- Drug
- Lead sponsor
- Kowa Research Institute, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 620 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 40
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Muscle Shoals, Alabama + 37 more
- Conditions
- B-cell Acute Lymphoblastic Leukemia, Large B-cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Marginal Zone Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Burkitt Lymphoma, Primary Mediastinal Large B-cell Lymphoma (PMBCL), Non Hodgkin Lymphoma, Mixed Phenotype Acute Leukemia
- Interventions
- Dose Level 1, VNX-101, Dose Level 2, VNX-101, Dose Level 3, VNX-101, Dose Level 4, VNX-101
- Genetic
- Lead sponsor
- Vironexis Biotherapeutics Inc.
- Industry
- Eligibility
- 13 Years to 90 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 11
- States / cities
- Duarte, California • Los Angeles, California • Denver, Colorado + 8 more
- Conditions
- Social Anxiety in Autistic Adults
- Interventions
- Placebo, Midomafetamine HCl, Therapy
- Drug · Behavioral
- Lead sponsor
- Resilient Pharmaceuticals
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Torrance, California
- Conditions
- Cachexia
- Interventions
- GTx-024, Placebo
- Drug
- Lead sponsor
- GTx
- Industry
- Eligibility
- Not listed
- Enrollment
- 159 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 50
- States / cities
- Anchorage, Alaska • Fayetteville, Arkansas • Corona, California + 41 more
- Conditions
- BAG3 Mutation Associated Dilated Cardiomyopathy
- Interventions
- ALXN2350
- Drug
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 7
- States / cities
- Birmingham, Alabama • Palo Alto, California • Boston, Massachusetts + 4 more
- Conditions
- Influenza, Human
- Interventions
- PF-07852352 Influenza saRNA 1, PF-07836391 Influenza saRNA, PF-07836394 Influenza saRNA, PF-07836395 Influenza saRNA, PF-07836396 Influenza saRNA, PF-07867246 Influenza saRNA, Placebo, Quadrivalent influenza vaccine (QIV), PF-07871987 Influenza saRNA, PF-07914705 Influenza saRNA, PF-07915048 Influenza saRNA
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 440 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 24
- States / cities
- Phoenix, Arizona • Walnut Creek, California • Greenacres City, Florida + 13 more
- Conditions
- Obesity, Overweight
- Interventions
- BI 3034701, Placebo matching BI 3034701
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years to 74 Years
- Enrollment
- 344 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • West Hills, California • Miami, Florida + 16 more
- Conditions
- Progranulin Mutation Carriers
- Interventions
- Nimodipine
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 30 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Relapsed and/or Refractory Multiple Myeloma
- Interventions
- BMS-986453, Fludarabine, Cyclophosphamide
- Drug
- Lead sponsor
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 187 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • Duarte, California • San Francisco, California + 8 more
- Conditions
- Advanced Cancer
- Interventions
- FP-1039
- Drug
- Lead sponsor
- Five Prime Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 2
- States / cities
- Detroit, Michigan • San Antonio, Texas
- Conditions
- Treatment Resistant Depression
- Interventions
- Intermittent theta-burst stimulation (iTBS) delivered to the L-DLPFC, Intermittent theta-burst stimulation (iTBS) delivered to the bilateral DLPFC
- Device
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- OSA - Obstructive Sleep Apnea
- Interventions
- AD109, AD504, Atomoxetine Hydrochloride, Placebo
- Drug
- Lead sponsor
- Apnimed
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 294 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 25
- States / cities
- Los Angeles, California • San Diego, California • Santa Ana, California + 21 more
- Conditions
- Squamous NSCLC
- Interventions
- CV09070101 mRNA vaccine (CVHNLC) 50 µg, CV09070101 mRNA vaccine (CVHNLC) 100 µg, CV09070101 mRNA vaccine (CVHNLC) 200 µg, CV09070101 mRNA vaccine (CVHNLC) 400 µg
- Biological
- Lead sponsor
- CureVac
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 2
- States / cities
- Fairfax, Virginia • Richmond, Virginia
- Conditions
- Peripheral T-cell Lymphoma
- Interventions
- Belinostat, CHOP
- Drug
- Lead sponsor
- Acrotech Biopharma Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 8
- States / cities
- New Haven, Connecticut • Athens, Georgia • Rochester, Minnesota + 5 more
- Conditions
- Chronic Kidney Disease
- Interventions
- 1.25 g PA21 (250 mg iron), 5.0 g PA21 (1,000 mg iron), 7.5 g PA21 (1,500 mg iron), 10.0 g PA21 (2,000 mg iron), 12.5 g PA21 (2,500 mg iron), Sevelamer hydrochloride
- Drug
- Lead sponsor
- Vifor Pharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 154 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 9
- States / cities
- Arvada, Colorado • Denver, Colorado • Pembroke Pines, Florida + 6 more
- Conditions
- Neoplasms
- Interventions
- Nenocorilant 200 mg, Nenocorilant 300 mg, Nenocorilant 400 mg, Nivolumab
- Drug
- Lead sponsor
- Corcept Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Chicago, Illinois • Grand Rapids, Michigan + 2 more
- Conditions
- Advanced Clear Cell Renal Cell Carcinoma, Advanced Renal Cell Carcinoma, Advanced Sarcomatoid Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Metastatic Sarcomatoid Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
- Interventions
- Biospecimen Collection, Bone Scan, CBM588 Capsules, Computed Tomography, Ipilimumab, Magnetic Resonance Imaging, Nivolumab
- Procedure · Biological
- Lead sponsor
- Osel, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Gastroesophageal Reflux Disease
- Interventions
- SSP-002358 (0.1 mg) + PPI, SSP-002358 (0.5 mg) + PPI, SSP-002358 (2.0 mg) + PPI, Placebo + PPI
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 480 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 62
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 58 more
- Conditions
- Hypotension, Pain
- Interventions
- Ropivacaine, Epinephrine
- Drug
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Primary Open Angle Glaucoma, Ocular Hypertension, Pigmentary Glaucoma, Pseudoexfoliative Glaucoma
- Interventions
- PF-03187207 and Latanoprost Vehicle, Latanoprost 0.005% and PF-03187207 Vehicle
- Drug
- Lead sponsor
- Bausch & Lomb Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 176 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 19
- States / cities
- Artesia, California • Newport Beach, California • Petaluma, California + 15 more